Weier Pharmaceutical released its 2026 interim report on August 22, 2026. The company's total operating revenue was 740 million yuan, net profit attributable to the parent company was 76.7829 million yuan, and net cash inflow from operating activities was 94.053 million yuan. The company's latest asset-liability ratio was 26.56%, gross margin was 27.61%, down 0.46 percentage points from the same period last year, latest ROE was 4.29%, and diluted earnings per share was 0.57 yuan. The company's latest total asset turnover was 0.29 times, inventory turnover was 2.55 times, number of shareholders was 5,464, and the top ten shareholders held 90.508 million shares, accounting for 66.83% of total share capital.
Nanjing Well Pharmaceutical Co LtdInterim report shows net profit and revenue, but no comparative expectations or market reaction; impact unclear.